P A Netland1, H Terada, C H Dohlman. 1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA.
Abstract
OBJECTIVE: This study aimed to review the authors clinical experience with glaucoma associated with keratoprosthesis in patients with severe corneal disease. DESIGN: The study design was a retrospective review of case series. PARTICIPANTS: The authors studied 55 eyes in 52 patients with keratoprostheses with follow-up of 21 +/- 16 months (range, 3-77 months). INTERVENTION: Glaucoma drainage devices were implanted in 36 eyes (35 Ahmed valves, 1 Krupin valve) with 21 +/- 15 months' follow-up (range, 3-64 months). MAIN OUTCOME MEASURES: Clinical outcome assessment included vision, intraocular pressure (IOP), visual fields, optic disc appearance, and identification of complications. RESULTS: Glaucoma was found in the majority (64%) of eyes treated with keratoprostheses, identified in 20 eyes (36%) before surgery and an additional 15 eyes (28%) after surgery. Of the 36 eyes treated with glaucoma drainage devices, IOP was controlled in 29 eyes (81%), with 9 eyes (25%) requiring additional medications. Continued progression of glaucoma occurred in 5 (14%) of 36 eyes with keratoprostheses and glaucoma drainage implants (4 of these eyes had advanced glaucomatous optic nerve damage before surgery). There were nine nonvision-threatening complications due to drainage implants. Compared with the preoperative visual acuity, vision was markedly improved in 63%, unchanged in 17%, and worse in 20% of eyes after keratoprosthesis surgery. CONCLUSION: Elevation of IOP is common in patients with keratoprosthesis, and prevention or treatment with glaucoma drainage implants is effective.
OBJECTIVE: This study aimed to review the authors clinical experience with glaucoma associated with keratoprosthesis in patients with severe corneal disease. DESIGN: The study design was a retrospective review of case series. PARTICIPANTS: The authors studied 55 eyes in 52 patients with keratoprostheses with follow-up of 21 +/- 16 months (range, 3-77 months). INTERVENTION: Glaucoma drainage devices were implanted in 36 eyes (35 Ahmed valves, 1 Krupin valve) with 21 +/- 15 months' follow-up (range, 3-64 months). MAIN OUTCOME MEASURES: Clinical outcome assessment included vision, intraocular pressure (IOP), visual fields, optic disc appearance, and identification of complications. RESULTS:Glaucoma was found in the majority (64%) of eyes treated with keratoprostheses, identified in 20 eyes (36%) before surgery and an additional 15 eyes (28%) after surgery. Of the 36 eyes treated with glaucoma drainage devices, IOP was controlled in 29 eyes (81%), with 9 eyes (25%) requiring additional medications. Continued progression of glaucoma occurred in 5 (14%) of 36 eyes with keratoprostheses and glaucoma drainage implants (4 of these eyes had advanced glaucomatous optic nerve damage before surgery). There were nine nonvision-threatening complications due to drainage implants. Compared with the preoperative visual acuity, vision was markedly improved in 63%, unchanged in 17%, and worse in 20% of eyes after keratoprosthesis surgery. CONCLUSION: Elevation of IOP is common in patients with keratoprosthesis, and prevention or treatment with glaucoma drainage implants is effective.
Authors: Roheena Kamyar; Jennifer S Weizer; Fernando Heitor de Paula; Joshua D Stein; Sayoko E Moroi; Denise John; David C Musch; Shahzad I Mian Journal: Cornea Date: 2012-02 Impact factor: 2.651
Authors: Christopher J Rudnisky; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Jared D Ament; Brian J Zerbe; Joseph B Ciolino Journal: Ophthalmology Date: 2012-02-22 Impact factor: 12.079
Authors: Jennifer I Lim; Lindsay Machen; Andrea Arteaga; Faris I Karas; Robert Hyde; Dingcai Cao; Marcia Niec; Thasarat S Vajaranant; M Soledad Cortina Journal: Retina Date: 2018-09 Impact factor: 4.256